On Demand Webinar

The transition from traditional 2D cell cultures to 3D tumor models has revolutionized preclinical oncology research by providing more physiologically relevant environments for studying tumor biology and drug responses. The advent of immunotherapies and stroma-targeted therapies has dramatically increased the need for more complex in vitro models replicating the TME and cancer immune interactions.

However, the complexity of 3D tumor models and the additional challenge of adding the complexity of recreating an in vitro immune and stroma microenvironment to test current combinatorial treatments also introduces significant difficulties. This comprehensive webinar will teach you the essential steps to design a robust 3D tumor model co-culture study.

Key Topics:

• Model Selection and Target Expression Validation: Choosing the most relevant tumor models and validating target expression.
  
  
• Donor Selection: Best practices for selecting donors to account for variability and ensure robust results.
  
  
• Assessment of Tumor to Immune Cell Ratio: Techniques for accurately assessing and optimizing the tumor-to-immune cell ratio in your cultures.
  
  
• Identifying the Right Controls: Strategies for selecting the appropriate controls to validate your study results.
  
  
• Choosing the Best Readouts: Insights on selecting the most informative readouts to capture meaningful data.
  
  

Meet Our Presenter:

Mara Gilardi, PhD, Immuno-oncology Subject Matter Expert, Champions Oncology

At the helm of Champions Oncology's immunology division, Mara synthesizes over 3 years of dedicated effort in translating cutting-edge research into clinical applications. Her core competencies include in-depth tumor microenvironment profiling with multiomics data, the development of ex vivo 2D-3D models and in vivo orthotopic models in immunodeficient and humanized animals, IHC and multiplex analysis and biomarker identification, which are instrumental in advancing our understanding and treatment of cancer.

Her mission is to bridge the gap between laboratory discoveries and patient care, driven by the ethical application of science and a commitment to improving clinical outcomes. Collaborating with industry leaders and our commercial and scientific teams, I am focused on fostering innovative R&D and marketing strategies while contributing to developing next-generation therapies.